SE9600070D0 - New oral pharmaceutical dosage forms - Google Patents

New oral pharmaceutical dosage forms

Info

Publication number
SE9600070D0
SE9600070D0 SE9600070A SE9600070A SE9600070D0 SE 9600070 D0 SE9600070 D0 SE 9600070D0 SE 9600070 A SE9600070 A SE 9600070A SE 9600070 A SE9600070 A SE 9600070A SE 9600070 D0 SE9600070 D0 SE 9600070D0
Authority
SE
Sweden
Prior art keywords
oral pharmaceutical
pharmaceutical dosage
dosage form
dosage forms
new oral
Prior art date
Application number
SE9600070A
Other languages
English (en)
Inventor
Helene Depui
Per Johan Lundberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400968&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9600070(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9600070A priority Critical patent/SE9600070D0/sv
Publication of SE9600070D0 publication Critical patent/SE9600070D0/sv
Priority to UA97104950A priority patent/UA46012C2/uk
Priority to KR1019970706234A priority patent/KR100483870B1/ko
Priority to CN96193595A priority patent/CN1116899C/zh
Priority to AU13239/97A priority patent/AU712571B2/en
Priority to HU9904095A priority patent/HU228569B1/hu
Priority to EP03011903A priority patent/EP1352660A1/en
Priority to SK1177-97A priority patent/SK283871B6/sk
Priority to ES96944724T priority patent/ES2201211T3/es
Priority to CA002213987A priority patent/CA2213987C/en
Priority to DE69628551T priority patent/DE69628551T2/de
Priority to AT96944724T priority patent/ATE242006T1/de
Priority to DK96944724T priority patent/DK0814839T3/da
Priority to JP52512997A priority patent/JP4638964B2/ja
Priority to SI9630626T priority patent/SI0814839T1/xx
Priority to PT96944724T priority patent/PT814839E/pt
Priority to RU97116843/14A priority patent/RU2158138C2/ru
Priority to PCT/SE1996/001735 priority patent/WO1997025064A1/en
Priority to NZ325975A priority patent/NZ325975A/xx
Priority to CZ19972748A priority patent/CZ294255B6/cs
Priority to MX9706767A priority patent/MX9706767A/es
Priority to IL12165096A priority patent/IL121650A/xx
Priority to TR97/00915T priority patent/TR199700915T1/xx
Priority to EP10180339A priority patent/EP2275139A1/en
Priority to EE9700194A priority patent/EE04003B1/xx
Priority to PL96322174A priority patent/PL187074B1/pl
Priority to BR9607476A priority patent/BR9607476A/pt
Priority to EP96944724A priority patent/EP0814839B1/en
Priority to ARP960105900A priority patent/AR005282A1/es
Priority to TW085116137A priority patent/TW452495B/zh
Priority to ZA9610936A priority patent/ZA9610936B/xx
Priority to SA96170540A priority patent/SA96170540B1/ar
Priority to MYPI97000059A priority patent/MY119212A/en
Priority to IS4546A priority patent/IS2368B/is
Priority to NO19974069A priority patent/NO327245B1/no
Priority to HK98100845A priority patent/HK1001761A1/xx
Priority to HK98111787A priority patent/HK1017991A1/xx
Priority to US09/471,958 priority patent/US6365184B1/en
Priority to US10/090,882 priority patent/US6613354B2/en
Priority to US10/620,000 priority patent/US7488497B2/en
Priority to US12/368,076 priority patent/US8114435B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9600070A 1996-01-08 1996-01-08 New oral pharmaceutical dosage forms SE9600070D0 (sv)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SE9600070A SE9600070D0 (sv) 1996-01-08 1996-01-08 New oral pharmaceutical dosage forms
MX9706767A MX9706767A (es) 1996-01-08 1996-12-20 Formas orales de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y una droga antiinflamatoria no esteroide (daine).
BR9607476A BR9607476A (pt) 1996-01-08 1996-12-20 Formas de dosagem farmacêutica oral e em tablete processo para preparar a dosagem fixadx e para tratar efeitos colaterais gastrointestinais associados ao tratamento com nsaid em mamíferos e no homem e uso da forma de dosagem
SK1177-97A SK283871B6 (sk) 1996-01-08 1996-12-20 Viaczložková tabletovaná lieková forma, spôsob jej výroby a jej použitie
EP96944724A EP0814839B1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
CN96193595A CN1116899C (zh) 1996-01-08 1996-12-20 含质子泵抑制剂和nsaid的口服药物剂型
AU13239/97A AU712571B2 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
HU9904095A HU228569B1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
EP03011903A EP1352660A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
CZ19972748A CZ294255B6 (cs) 1996-01-08 1996-12-20 Orální farmaceutické lékové formy obsahující inhibitor protonové pumpy a NSAID
ES96944724T ES2201211T3 (es) 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica orales que comprenden un inhibidor de bomba de protones y un nsaid.
CA002213987A CA2213987C (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
DE69628551T DE69628551T2 (de) 1996-01-08 1996-12-20 Oral anzuwendende pharmazeutische dosierungsformen,enthaltend einem protonenpunpeninibitor und einen nicht-steriodalen antiinflamatorischen wirkstoff
AT96944724T ATE242006T1 (de) 1996-01-08 1996-12-20 Oral anzuwendende pharmazeutische dosierungsformen,enthaltend einem protonenpunpeninibitor und einen nicht- steriodalen antiinflamatorischen wirkstoff
DK96944724T DK0814839T3 (da) 1996-01-08 1996-12-20 Orale, farmaceutiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID
JP52512997A JP4638964B2 (ja) 1996-01-08 1996-12-20 プロトンポンプ阻害剤およびｎｓａｉｄからなる経口用医薬剤形
SI9630626T SI0814839T1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
PT96944724T PT814839E (pt) 1996-01-08 1996-12-20 Formas de dosagem farmaceutica orais que contem um inibidor da bomba de protoes e um faine
KR1019970706234A KR100483870B1 (ko) 1996-01-08 1996-12-20 양성자펌프억제제및비스테로이드성항염증약물을포함하는경구제약제형
PCT/SE1996/001735 WO1997025064A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
IL12165096A IL121650A (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and non steroidal antinflammatory drug
UA97104950A UA46012C2 (uk) 1996-01-08 1996-12-20 Фармацевтична лікарська форма для перорального прийому, яка містить інгібітор протонного насоса і засіб нестероїдної протизапальної терапії, спосіб її одержання (варіанти) та спосіб лікування побічних ефектів, що виникають у шлунково-кишковому тракті внаслідок лікування засобами нестероїдної протизапальної терапії
RU97116843/14A RU2158138C2 (ru) 1996-01-08 1996-12-20 Фармацевтические лекарственные формы для перорального приема, содержащие ингибитор протонного насоса и средство нестероидной противовоспалительной терапии
NZ325975A NZ325975A (en) 1996-01-08 1996-12-20 Enteric coated oral pharmaceutical compositions comprising a proton pump inhibitor and a nsaid
TR97/00915T TR199700915T1 (xx) 1996-01-08 1996-12-20 Oral ispen�iyari dozaj formlar�.
EP10180339A EP2275139A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
EE9700194A EE04003B1 (et) 1996-01-08 1996-12-20 Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja NSAID
PL96322174A PL187074B1 (pl) 1996-01-08 1996-12-20 Doustna farmaceutyczna postać dawkowana, sposób wytwarzania doustnej farmaceutycznej postaci dawkowanej i zastosowanie doustnej farmaceutycznej postaci dawkowanej
ARP960105900A AR005282A1 (es) 1996-01-08 1996-12-26 Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
TW085116137A TW452495B (en) 1996-01-08 1996-12-27 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
ZA9610936A ZA9610936B (en) 1996-01-08 1996-12-30 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
SA96170540A SA96170540B1 (ar) 1996-01-08 1996-12-31 صور لجرعات صيدلانية تعطى عن طريق الفم وتشتمل على مثبط لمضخة البروتون nasid proton pump
MYPI97000059A MY119212A (en) 1996-01-08 1997-01-07 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
IS4546A IS2368B (is) 1996-01-08 1997-08-19 Lyfjaform til inntöku um munn sem fela í sér róteindadælutálma og bólgueyðandi lyf án stera (NSAID-lyf)
NO19974069A NO327245B1 (no) 1996-01-08 1997-09-04 Orale farmasoytiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID, fremgangsmate for fremstilling samt anvendelse derav.
HK98100845A HK1001761A1 (en) 1996-01-08 1998-02-05 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
HK98111787A HK1017991A1 (en) 1996-01-08 1998-11-06 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
US09/471,958 US6365184B1 (en) 1996-01-08 1999-12-23 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US10/090,882 US6613354B2 (en) 1996-01-08 2002-03-04 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US10/620,000 US7488497B2 (en) 1996-01-08 2003-07-14 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US12/368,076 US8114435B2 (en) 1996-01-08 2009-02-09 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600070A SE9600070D0 (sv) 1996-01-08 1996-01-08 New oral pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
SE9600070D0 true SE9600070D0 (sv) 1996-01-08

Family

ID=20400968

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600070A SE9600070D0 (sv) 1996-01-08 1996-01-08 New oral pharmaceutical dosage forms

Country Status (35)

Country Link
US (4) US6365184B1 (sv)
EP (3) EP1352660A1 (sv)
JP (1) JP4638964B2 (sv)
KR (1) KR100483870B1 (sv)
CN (1) CN1116899C (sv)
AR (1) AR005282A1 (sv)
AT (1) ATE242006T1 (sv)
AU (1) AU712571B2 (sv)
BR (1) BR9607476A (sv)
CA (1) CA2213987C (sv)
CZ (1) CZ294255B6 (sv)
DE (1) DE69628551T2 (sv)
DK (1) DK0814839T3 (sv)
EE (1) EE04003B1 (sv)
ES (1) ES2201211T3 (sv)
HK (2) HK1001761A1 (sv)
HU (1) HU228569B1 (sv)
IL (1) IL121650A (sv)
IS (1) IS2368B (sv)
MX (1) MX9706767A (sv)
MY (1) MY119212A (sv)
NO (1) NO327245B1 (sv)
NZ (1) NZ325975A (sv)
PL (1) PL187074B1 (sv)
PT (1) PT814839E (sv)
RU (1) RU2158138C2 (sv)
SA (1) SA96170540B1 (sv)
SE (1) SE9600070D0 (sv)
SI (1) SI0814839T1 (sv)
SK (1) SK283871B6 (sv)
TR (1) TR199700915T1 (sv)
TW (1) TW452495B (sv)
UA (1) UA46012C2 (sv)
WO (1) WO1997025064A1 (sv)
ZA (1) ZA9610936B (sv)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
ES2274625T3 (es) * 1998-05-18 2007-05-16 Takeda Pharmaceutical Company Limited Comprimidos desintegrables en la boca que comprenden un bencimidazol.
SI1100469T1 (sv) * 1998-07-28 2005-08-31 Takeda Pharmaceutical
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US7737147B2 (en) * 2000-07-27 2010-06-15 Thomas Nadackal Thomas Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP4705747B2 (ja) * 2001-05-30 2011-06-22 ユーロセルティック ソシエテ アノニム 薬剤組成物
DK1411900T4 (da) * 2001-06-01 2014-01-27 Pozen Inc Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1429742B1 (en) 2001-09-28 2011-05-04 McNeil-PPC, Inc. Modified release dosage forms
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
FR2831820B1 (fr) * 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003261281A1 (en) * 2002-07-29 2004-02-16 Nicox S.A. Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
EP1534278A4 (en) 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
DE10244504A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
EP1562555A2 (en) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US20050288373A1 (en) * 2002-10-24 2005-12-29 Ron Eyal S Methods of treating various conditions by administration of sustained release L-arginine
US20060029668A1 (en) * 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004056336A2 (en) * 2002-12-20 2004-07-08 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
CN100488507C (zh) * 2003-05-08 2009-05-20 尼科梅德有限责任公司 含有泮托拉唑作为活性成分的剂型
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1675619A4 (en) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
US20070065513A1 (en) * 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005074930A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
MXPA06015131A (es) * 2004-06-29 2007-03-26 Nycomed Danmark Aps Manufactura de composiciones farmaceuticas con liberacion precipitada de farmacos insolubles en agua y composiciones farmaceuticas obtenidas por medio del proceso de la invencion.
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP2494992A1 (en) * 2004-08-24 2012-09-05 Merck Sharp & Dohme Corp. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
CA2595651A1 (en) * 2005-01-24 2006-08-03 Enos Pharmaceuticals, Inc. Methods of treating various conditions by administration of sustained release l-arginine
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
CA2511158A1 (en) * 2005-06-29 2006-12-29 Medical Futures Inc. Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against nsaid gastropathy
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20070043096A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
CA2617164A1 (en) * 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
JP2009524592A (ja) * 2005-12-20 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
HUE029222T2 (en) * 2006-01-27 2017-02-28 Univ Yale Fast acting gastric acid secretion inhibitor
EP1837016A3 (en) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP1834634A3 (en) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Pharmaceutical multiple-unit composition
CA2647497C (en) 2006-04-04 2016-01-12 Cogentus Pharmaceuticals, Inc. Oral dosage forms including an antiplatelet agent and an acid inhibitor
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
WO2007129178A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008018825A1 (en) * 2006-08-10 2008-02-14 Astrazeneca Ab Oral polyvinyl alcohol capsules comprising proton pump inhibitors
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
EP2068841B1 (en) * 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
ES2494848T3 (es) 2006-11-21 2014-09-16 Mcneil-Ppc, Inc. Suspensiones analgésicas de liberación modificada
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
WO2008140459A1 (en) * 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140460A1 (en) * 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
CA2600147A1 (en) * 2007-06-11 2008-12-11 Nathan Bryson Combination for treatment of diabetes mellitus
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
CN101969933B (zh) * 2008-01-25 2016-03-30 杜奥-戈公司 通过包覆物结合的口服药物的组合
FR2926724B1 (fr) * 2008-01-25 2010-06-18 Duo Ge Nouvelle forme pharmaceutique orale.
FR2926723B1 (fr) * 2008-01-25 2010-06-18 Duo Ge Associations pharmaceutiques orales.
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
CA2765866C (en) * 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
US20110144207A1 (en) * 2008-08-14 2011-06-16 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms
WO2010029335A1 (en) 2008-09-09 2010-03-18 Astrazeneca Uk Limited Method for delivering a pharmaceutical composition to patient in need thereof
US8246988B2 (en) * 2009-01-05 2012-08-21 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
CA2748728C (en) * 2009-01-05 2017-01-03 Mcneil-Ppc, Inc. Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
WO2010078541A1 (en) * 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
WO2010121328A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of indomethacin
CN106420667A (zh) 2009-04-24 2017-02-22 伊休蒂卡有限公司 双氯芬酸的新剂型
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EP2496219A1 (en) * 2009-06-29 2012-09-12 McNeil-PPC, Inc. Pharmaceutical tablet containing a liquid filled capsule
RU2010108361A (ru) * 2010-03-09 2011-09-20 Гаврилова Эмилия Евгеньевна (RU) Набор лечебных средств
WO2011144994A1 (en) * 2010-05-21 2011-11-24 Lupin Limited Pharmaceutical compositions of nsaid and acid inhibitor
WO2012018056A1 (ja) * 2010-08-03 2012-02-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 圧縮組成物
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
EP2647381A4 (en) 2010-12-03 2015-12-23 Takeda Pharmaceutical MELTING TABLET
AU2011343190B2 (en) 2010-12-16 2016-12-08 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2012213056A1 (en) * 2011-02-02 2013-07-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
CN106117343B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
TR201103752A2 (tr) 2011-04-18 2012-11-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Tiyokolşikozit, diklofenak ve lansoprazol kombinasyonları.
JP2014516080A (ja) * 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
CN102406938A (zh) * 2011-11-29 2012-04-11 北京阜康仁生物制药科技有限公司 一种抗血栓的药物组合物
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
SG11201505320TA (en) * 2012-03-20 2015-08-28 Bagó S A Lab Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
KR101907690B1 (ko) * 2012-04-12 2018-10-15 한미약품 주식회사 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
MY184077A (en) 2013-05-21 2021-03-17 Takeda Pharmaceuticals Co Orally disintegrable tablet
WO2015150943A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Pharmaceutical composition of nsaid and ppi or salt thereof
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
KR101723266B1 (ko) * 2014-08-13 2017-04-05 영남대학교 산학협력단 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 경구용 속방형 조성물 및 그 제조방법
CN104208039B (zh) * 2014-08-26 2017-05-03 杭州新诺华医药有限公司 一种萘普生埃索美拉唑镁肠溶制剂及制备方法
WO2016102661A1 (en) * 2014-12-23 2016-06-30 Krka, D.D., Novo Mesto Pharmaceutical tablet composition
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017018473A1 (ja) 2015-07-30 2017-02-02 武田薬品工業株式会社 錠剤
CN106668017A (zh) * 2015-11-11 2017-05-17 上海星泰医药科技有限公司 萘普生和埃索美拉唑镁复方肠溶胶囊及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
TR201718099A2 (tr) 2017-11-16 2019-06-21 Mehmet Nevzat Pisak Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar
WO2019135725A1 (en) 2018-01-03 2019-07-11 Pisak Mehmet Nevzat Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation
TWI804571B (zh) 2018-02-02 2023-06-11 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2019240310A1 (ko) * 2018-06-14 2019-12-19 한국유나이티드제약 주식회사 아세클로페낙과 에스오메프라졸을 포함하는 복합제제 및 그 제조방법
RU2732297C2 (ru) * 2018-11-14 2020-09-15 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные нестероидных противовоспалительных средств
EP4070789A4 (en) * 2020-01-23 2024-01-24 Hanmi Pharm Ind Co Ltd PHARMACEUTICAL COMPOSITE FORMULATION WITH PROTON PUMP INHIBITOR AND ANTACID
CN115379838A (zh) * 2020-04-13 2022-11-22 怡诺安有限公司 包含苯并咪唑衍生物化合物的药物组合物
EP4167373A1 (en) * 2021-08-26 2023-04-19 Contemporary Amperex Technology Co., Limited Liquid bag, battery cell, battery and power device
WO2023129069A2 (en) * 2021-12-29 2023-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising naproxen and esomeprazole
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016744A (en) * 1975-05-28 1977-04-12 Hoffmann-La Roche Inc. Applied instrumentation providing tabletting compression force
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4263328A (en) * 1979-10-26 1981-04-21 General Foods Corporation Tableted gasified candy
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4602007A (en) * 1980-05-08 1986-07-22 Abbott Laboratories Salicylate culture media for inactivation of bacterial growth inhibitors
US4340582A (en) 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
DE3586600T2 (de) 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
US4568560A (en) 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US4948581A (en) * 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
IN171746B (sv) 1989-11-02 1992-12-26 Mcneil Ppc Inc
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
CA2083606C (en) 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
JP3142919B2 (ja) 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
PL170554B1 (pl) 1991-12-17 1996-12-31 Fuisz Technologies Ltd Sposób wytwarzania kompozycji przeciwwrzodowej PL PL PL
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
SG42869A1 (en) 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
US5700947A (en) 1993-10-06 1997-12-23 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
WO1995010264A1 (fr) 1993-10-12 1995-04-20 Tokyo Tanabe Company Limited Tablette contenant des granules entero-solubles
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
GB2285989A (en) 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
KR100387359B1 (ko) 1994-05-10 2003-08-27 니콕스 에스. 에이. 항-염증성,비알러지성및항-혈전성을가지는니트로화합물들과그들의조성물들
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
RU2160094C2 (ru) 1994-07-08 2000-12-10 Астра Актиеболаг Таблетированная многоединичная лекарственная форма, способ ее получения, упаковка и способ ингибирования секреции желудочной кислоты и/или лечения желудочно-кишечных воспалительных заболеваний
US5763422A (en) 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
JPH08301763A (ja) 1995-04-28 1996-11-19 Dainippon Pharmaceut Co Ltd 易溶性粉末状医薬組成物およびその製造方法
US5955451A (en) 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
TR199901101T2 (xx) 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6383982B1 (en) * 1999-05-11 2002-05-07 Mitsui Chemicals, Inc. Color developer composition, aqueous dispersion, recording sheet and color developing ink
HUP0201637A3 (en) * 1999-06-07 2004-05-28 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
EP2275139A1 (en) 2011-01-19
PL187074B1 (pl) 2004-05-31
UA46012C2 (uk) 2002-05-15
PL322174A1 (en) 1998-01-19
IS2368B (is) 2008-06-15
CN1183048A (zh) 1998-05-27
ZA9610936B (en) 1997-07-08
PT814839E (pt) 2003-10-31
US8114435B2 (en) 2012-02-14
CA2213987C (en) 2006-08-15
ATE242006T1 (de) 2003-06-15
IL121650A0 (en) 1998-02-08
IL121650A (en) 2003-03-12
NO974069L (no) 1997-10-17
KR100483870B1 (ko) 2005-09-30
ES2201211T3 (es) 2004-03-16
MY119212A (en) 2005-04-30
US20090297594A1 (en) 2009-12-03
AU1323997A (en) 1997-08-01
EP1352660A1 (en) 2003-10-15
HUP9904095A2 (hu) 2000-06-28
HK1001761A1 (en) 1998-07-10
DE69628551D1 (de) 2003-07-10
HUP9904095A3 (en) 2002-03-28
US20020155153A1 (en) 2002-10-24
US6613354B2 (en) 2003-09-02
CZ274897A3 (cs) 1998-01-14
TR199700915T1 (xx) 1997-11-21
EP0814839A1 (en) 1998-01-07
BR9607476A (pt) 1997-12-23
US6365184B1 (en) 2002-04-02
EE04003B1 (et) 2003-04-15
AR005282A1 (es) 1999-04-28
EE9700194A (et) 1998-02-16
WO1997025064A1 (en) 1997-07-17
DK0814839T3 (da) 2003-09-22
US20040022846A1 (en) 2004-02-05
TW452495B (en) 2001-09-01
CA2213987A1 (en) 1997-07-17
NO327245B1 (no) 2009-05-18
JPH11501948A (ja) 1999-02-16
US7488497B2 (en) 2009-02-10
CZ294255B6 (cs) 2004-11-10
AU712571B2 (en) 1999-11-11
HU228569B1 (en) 2013-04-29
JP4638964B2 (ja) 2011-02-23
SA96170540B1 (ar) 2005-12-18
CN1116899C (zh) 2003-08-06
MX9706767A (es) 1997-11-29
DE69628551T2 (de) 2004-05-06
NO974069D0 (no) 1997-09-04
RU2158138C2 (ru) 2000-10-27
IS4546A (is) 1997-08-19
SI0814839T1 (en) 2003-12-31
SK117797A3 (en) 1998-04-08
EP0814839B1 (en) 2003-06-04
NZ325975A (en) 1999-02-25
HK1017991A1 (en) 1999-12-10
KR19980702827A (ko) 1998-08-05
SK283871B6 (sk) 2004-03-02

Similar Documents

Publication Publication Date Title
SE9600070D0 (sv) New oral pharmaceutical dosage forms
MX9604354A (es) Nueva forma de dosis farmaceutica oral.
TR199700917T1 (xx) Oral farmas�tik dozaj formlar�.
SE9600071D0 (sv) New oral formulation of two active ingredients I
DE69636104D1 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreigabe von Protonenpumpen-Hemmern
ATE232091T1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren
CA2214027A1 (en) Multiple unit effervescent dosage forms comprising proton pump inhibitor
CA2170647A1 (en) Multiple unit tableted dosage form i
SE9402431D0 (sv) New tablet formulation
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
RU99118887A (ru) Применение ингибиторов желудочно-кишечной липазы
SE9700885D0 (sv) New pharmaceutical formulation
YU34199A (sh) Primena inhibitora gastrointestinalne lipaze
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
WO2002069968A8 (en) New use
ATE59551T1 (de) Feste orale arzneiformen mit gestaffelter wirkung zur verabreichung von wirkstoffen mit geschwuere erzeugender nebenwirkung.
JO1881B1 (en) Formula II for multi unit disc calibration
RU97119670A (ru) Способ профилактики иксодовых клещевых боррелиозов
RU99127981A (ru) Способ лечения рецидивирующего фурункулеза
JO1880B1 (en) Format 1 for multi-unit calibration discs